SILO PHARMA, INC. Contract Liability (Deferred Revenue)
SILO PHARMA, INC. (SILO) had Contract Liability (Deferred Revenue) of $33.24 thousand as of 2026-04-01, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-13
- 2026-04-01: Contract with Customer, Liability, Current $33.24K.
- 2026-03-31: Contract with Customer, Liability, Current $72.10K.
- 2025-12-31: Contract with Customer, Liability, Current $72.10K.
- 2025-09-30: Contract with Customer, Liability, Current $72.10K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-04-01 | $33.24K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $72.10K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $72.10K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $72.10K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $72.10K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $72.10K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $72.10K POS AM · filed 2026-04-14 |
| 2024-09-30 | $72.10K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $72.10K 10-Q · filed 2024-08-13 |
| 2023-12-31 | $72.10K 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |